Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thromboembolism × edoxaban × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7 Venous Thrombosis 5 Venous Thromboembolism 3 Pulmonary Embolism 2 Thrombosis 1 Thromboembolism 1 Myeloproliferative Disorders 1 Embolism 1

Interventions

Enoxaparin 4 Dalteparin 4 Tinzaparin 3 Saline Solution 3 Gemcitabine 3 Warfarin 2 Heparin, Low-Molecular-Weight 2 Heparin 2 Fondaparinux 2 Aspirin 2 130-nm albumin-bound paclitaxel 2 palbociclib 1 enoxaparin sodium 1 edoxaban 1 apixaban 1 alvocidib 1 Watchful Waiting 1 Tranexamic Acid 1 Sodium Chloride 1 Sodium Bicarbonate 1 Rivaroxaban 1 Pentetic Acid 1 PEGPH20 1 Nadroparin 1 Minocycline 1 Lenalidomide 1 Ketoconazole 1 Immunoenzyme Techniques 1 High-Energy Shock Waves 1 Fluoridation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04072068 2023-05-30

EDOI

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 4 Completed

Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡